17 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2039
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2040 · High confidence
Also notable
Ends May 2043 · Medium confidence
RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use
US 11,162,114
Granted 2021. Computed term ends 2040.
RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use
US 12,624,369
A family of 8 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 2, 2027The maintenance fee for RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (US 11,859,181) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (US 11,926,843) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (2022) | 4 in force | to May 2043 |
| DNA Modifying Enzymes and Active Fragments and Variants Thereof and Methods of Use | 4 in force | to Nov 2042 |
| RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (2024) | 3 in force | to Jan 2043 |
| RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use (2019) | 3 in force | to Jun 2040 |
| Polypeptides Useful for Gene Editing and Methods of Use | 2 in force | to Jul 2042 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,338,455 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use held by Life Edit Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,926,843 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use held by LifeEDIT Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 12,188,018 | Polypeptides Useful for Gene Editing and Methods of Use held by Life Edit Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,162,114 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use held by Lifeedit Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,981,916 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use held by LifeEDIT Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,252,706 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use held by Life Edit Therapeutics, Inc. In force · Low confidence | In force | Low confidence | |
| US 11,859,181 | RNA-Guided Nucleases and Active Fragments and Variants Thereof and Methods of Use held by Lifeedit Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 11,981,940 | DNA Modifying Enzymes and Active Fragments and Variants Thereof and Methods of Use held by Life Edit Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,188,061 | Nucleic Acid Molecules Encoding DNA Modifying Enzymes and Active Fragments and Variants Thereof and Compositions Comprising the Same held by Life Edit Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,188,062 | DNA Modifying Enzymes and Active Fragments and Variants Thereof and Methods of Use held by Life Edit Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 17: 20 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
8 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.